[Immunomodulatory therapy of autoimmune diseases : Quo vadis?].

about

[Optimization of therapy of autoimmune diseases of the eye : Novel approaches].

P2860

Q52852661-778FFE82-2572-461E-A17A-476FD2C18557

P2860

[Immunomodulatory therapy of autoimmune diseases : Quo vadis?].

Item

http://www.wikidata.org/entity/Q52852647

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

[Immunomodulatory therapy of autoimmune diseases : Quo vadis?].

@en

[Immunomodulatory therapy of autoimmune diseases : Quo vadis?].

@nl

type

Item

label

[Immunomodulatory therapy of autoimmune diseases : Quo vadis?].

@en

[Immunomodulatory therapy of autoimmune diseases : Quo vadis?].

@nl

prefLabel

[Immunomodulatory therapy of autoimmune diseases : Quo vadis?].

@en

[Immunomodulatory therapy of autoimmune diseases : Quo vadis?].

@nl

P1476

[Immunomodulatory therapy of autoimmune diseases : Quo vadis?].

@en

P2093

F Hiepe

http://www.w3.org/2001/XMLSchema#string

P2860

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Biological effects of cyclosporin A: a new antilymphocytic agent

Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.

Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

New concepts in antimalarial use and mode of action in dermatology.

Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors.

Intravenous immunoglobulin in eye involvement.

Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice.

RNA interference as a novel and powerful tool in immunopharmacological research.

How to cope with pathogenic long-lived plasma cells in autoimmune diseases.

P2888

s00347-016-0263-3

P304

373-379

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S00347-016-0263-3

http://www.w3.org/2001/XMLSchema#string

P407

Af-Jarmal

P433

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

B Hoyer

P577

2016-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27155599

http://www.w3.org/2001/XMLSchema#string

[Immunomodulatory therapy of autoimmune diseases : Quo vadis?].

about

P2860

P2860

[Immunomodulatory therapy of autoimmune diseases : Quo vadis?].

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698